Alnylam Pharma (ALNY) Announces Initiation of ALN-AAT Phase 1/2 in Alpha-1 Liver Disease
Tweet Send to a Friend
Alnylam Pharma (NASDAQ: ALNY) has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE